The life expectancy of patients with mutations in the SLC34A2 gene is significantly lower than in patients without gene alterations in studies of breast (p < 0.042) and thymus (p < 0.0008) tumors (cBioPortal, TCGA: Breast invasive carcinoma, n = 1082, Thymoma, n = 122; Figure 3A-B). Here, SLC34A2 is linked to thymoma.